TPE:6949

2 stories mentioning TPE:6949Updated 45m ago

Every FINWIRES story that references TPE:6949, newest first.

PELL Bio-Med's Multi-chain CAR-T Technology Gets Patent in Japan

PELL Bio-Med Technology's (TPE:6949) multi-chain CAR-T technology, NKp30, secured a patent in Japan, according to a Thursday Taiwan Exchange filing.The patent, titled "Isolated Nucleic Acid Molecule Comprising NKp30 Transmembrane Domain and Chimeric Antigen Receptor Comprising the Same," was granted under application No. 2024-167934.The biomedical company said the technology can be applied to CAR-T treatment of solid tumors and could support the development of pipeline candidates for various solid-tumor indications.

TPE:6949

Asia79d ago

Pell Bio Med Unit Gets China's Regulatory Nod for Rheumatoid Arthritis Drug Trail

Pell Bio Med Technology (TPE:6949) unit Peptide (Shanghai) Pharmaceutical Technology secured approval from China's National Medical Products Administration (NMPA) to begin the Phase I clinical trial for its oral drug candidate PP011, according to a Tuesday Taiwan Exchange filing.The trial will be conducted in healthy subjects and targets rheumatoid arthritis (RA), marking the first human study for the novel therapy.The company said the development program is planned through Phase two and Phase three trials before potential new drug application submission.Phase one completion is expected in the first quarter of 2027, it said.

TPE:6949

Track with the FINWIRES app suite

FolioX

Track TPE:6949 in your portfolio

WheelAI

Analyze TPE:6949 options with the wheel strategy

StockInsider

See market sentiment on TPE:6949